CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 108 enrolled
Drug / intervention
Escitalopram +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02620150
NCT02620150Phase 4Completed
CompareCT.gov

SSRI Effects on Depression and Immunity in HIV/AIDS

University of Pennsylvania·interventional·Posted Dec 2, 2015·Updated May 7, 2024

In Brief

A Phase 4 clinical trial evaluating Escitalopram and Placebo for Depression and 2 related conditions. Completed, enrolled 108 participants across 1 site.

Detailed Summary

This is a 10 week, double-blind, placebo controlled trial to evaluate SSRI (Selective Serotonin Reuptake Inhibitor) effects for treatment of depression in HIV/AIDS with a focus on innate immunity and inflammation. Depressed population is HIV + on cART (Combination Antiretroviral Therapy), not currently on pharmacotherapy for depression. Subjects will complete computerized cognitive behavior therapy, CCBT for their depression. Blood samples collected for virologic, neuroendocrine, and immunologic evaluation. Our overarching hypothesis is that SSRI treatment of depression and improvement of depressive symptoms leads to increased innate immunity and decreased inflammation, resulting in better control of HIV disease and decreased morbidity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, HIV, AIDS
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2, 2015
Enrollment StartFeb 16, 2017
Primary CompletionMar 31, 2022
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 10.6 years ago

Interventions

Escitalopramdrug

10 week trial

Placeboother

10 week trial